Clin Osteol 2012; 17(2): 50-58

The risk of osteoporosis and fractures in patients with multiple sclerosisOriginal contributions

V.Zikán

Both women and men with multiple sclerosis (MS) are at increased risk of developing osteoporosis and fractures. The principal factor resulting in low bone mass and increased fracture risk in MS is immobility. The vitamin D deficiency, treatment with glucocortico­ ids and / or antidepressants and probably also own disease MS may contribute to development of osteoporosis. Osteoporosis-related fractures cause increased morbidity and mortality and add to the burden of having MS. Therefore, bone health assessment including bone mineral density measurement should be a part of the integral management of persons with MS. There are currently no guideli­ nes how to best prevent and treat osteoporosis in patients with MS. The work p treatment of osteoporosis in patients with MS.

Keywords: osteoporosis, fracture risk, multiple sclerosis, clinical guidelines

Published: December 11, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Zikán V. The risk of osteoporosis and fractures in patients with multiple sclerosis. Osteologický bulletin. 2012;17(2):50-58.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Compston A, Coles A Multiple sclerosis. Lancet 2008;372:1502-1517. Go to original source...
    2. Pugliatti M, Sotgiu S, Rosati G. The worldwide prevalence of multiple scleros Clin Neurol Neurosurg 2002;104:182-191. Go to original source...
    3. Hughes JM, Petit MA Biological underpinnings of Frost's mechanostat thres­ holds: the important role of osteocytes. J Musculoskelet Neuronal Interact 2010; 10:128-135.
    4. Sibley WA, Bamford CR, Clark K et al. A prospective study of physical trauma and multiple sclerosis. J Neurol Neurosurg Psychiatry 1991;54:584-589. Go to original source...
    5. Troiano RA, Jotkowitz A, Cook SD et al. Rate and types of fractures in steroid-treated multiple sclerosis patients. Neurology 1992;42:1389-1391. Go to original source...
    6. Nieves J, Cosman F, Herbert J et al. High prevalence of vitamin D reduced bone mass in multiple sclerosis. Neurology 1994;44:1687-1692. Go to original source...
    7. Cosman F, Nieves J, Herbert J et al. High-dose glucocorticoids in multiple sc rosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994;9:1097-1105. Go to original source...
    8. Cosman F, Nieves J, Komar L et al. Fracture history and bone loss in patients MS. Neurology 1998;51:1161-1165. Go to original source...
    9. Weinstock-Guttman B, Gallagher E, Baier M et al. Risk of bone loss in men with multiple sclerosis. Mult Scler 2004;10:170-175. Go to original source...
    10. Logan WC jr, Sloane R, Lyles KW et al. Incidence of fractures in a cohort of terans with chronic multiple sclerosis or traumatic spinal cord injury. Arch Phys Med Rehabil 2008;89:237-243. Go to original source...
    11. Bazelier MT, van Staa T, Uitdehaag BM et al. The risk of fracture in patients multiple sclerosis: the UK general practice research database. J Bone Miner Res 2011;26:2271-2279. Go to original source...
    12. Kampman MT, Eriksen EF, Holm0y T. Multiple sclerosis, a cause of secondary osteoporosis? What is the evidence and what are the clinical implications? Acta Neurol Scand Suppl 2011;191:44-49. Go to original source...
    13. Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler 2010;16:1031-1043. Go to original source...
    14. Marrie RA, Cutter G, Tyry T, Vollmer T. A cross-sectional study of bone health in multiple sclerosis. Neurology 2009;73:1394-1398. Go to original source...
    15. Bazelier MT, Bentzen J, Vestergaard P et al. The risk of fracture in incident m tiple sclerosis patients: The Danish National Health Registers. Mult Scler 2012; [v tisku] Go to original source...
    16. van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007; 254:581-590. Go to original source...
    17. Moen SM, Celius EG, Sandvik L et al. Low bone mass in newly diagnosed mul­ tiple sclerosis and clinically isolated syndrome. Neurology 2011;77:151-157. Go to original source...
    18. Nilsagard Y, Lundholm C, Denison E et al. Predicting accidental falls in people with multiple sclerosis - a longitudinal study. Clin Rehabil 2009;23:259-269. Go to original source...
    19. Jbterson EW, Cho CC, von Koch L et al. Injurious falls among middle aged and older adults with multiple sclerosis. Arch Phys Med Rehabil 2008;89:1031-1037. Go to original source...
    20. Finlayson ML, Peterson EW, Cho CC. Risk factors for falling among people aged 45 to 90 years with multiple sclerosis. Arch Phys Med Rehabil 2006;87:1274-1279. Go to original source...
    21. Rochefort GY, Pallu S, Benhamou CL. Osteocyte: the unrecognized side of bone tissue. Osteoporos Int 2010;21:1457-1469. Go to original source...
    22. Aguirre JI, Plotkin LI, Stewart SA et al. Osteocyte apoptosis is induced by weig lessness in mice and precedes osteoclast recruitment and bone loss. J Bone Miner Res 2006;21:605-615. Go to original source...
    23. Shigematsu T, Miyamoto A, Mukai C et al. Changes in bone and calcium meta­ bolism with space flight. Osteoporos Int 1997; 7 Suppl 3:S63-67. Go to original source...
    24. Minaire P. Immobilization osteoporosis: a review. Clin Rheumatol 1989;8 Suppl 2:95-103. Go to original source...
    25. Lin C, Jiang X, Dai Z et al. Sclerostin mediates bone response to mechanical un­ loading through antagonizing Wnt/beta-catenin signaling. J Bone Miner Res 2009;10:1651-1661. Go to original source...
    26. Tian X, Jee WS, Li X et al. Sclerostin antibody increases bone mass by stimula­ ting bone formation and inhibiting bone resorption in a hindlimb-immobilization rat model. Bone 2011;48:197-201. Go to original source...
    27. Waldorff EI, Christenson KB, Cooney LA et al. Microdamage repair and remo­ deling requires mechanical loading. J Bone Miner Res 2010;25:734-745. Go to original source...
    28. Jiang SD, Da 2006;17:180-192.
    29. Slade JM, Bickel CS, Modlesky CM et al. Trabecular bone is more deteriora spinal cord injured versus estrogen-free postmenopausal women. Osteoporos Int 2005;16:263-272. Go to original source...
    30. Jorgensen L, Jacobsen BK, Wilsgaard T et al. Walking after stroke: does i ter? Changes in bone mineral density within the first 12 months after stroke. A longitudinal study. Osteoporos Int 2000;11:381-387. Go to original source...
    31. Kurtzke JF. Rating neurologic impairment in multiple scle ability status scale (EDSS). Neurology 1983;33(11):1444-1452. Go to original source...
    32. Schwid SR, Goodman AD, Edward PJ et al. Sporadic corticost teoporosis in multiple sclerosis. Arch Neurol 1996;53:753-757. Go to original source...
    33. Ozgocmen S, Bulut S, Ilhan N et al. Vitamin D deficiency and reduced bone mi­ neral density in multiple sclerosis: effect pacity. J Bone Miner Metab 2005;23:309-313. Go to original source...
    34. Hotermans C, Dive D, Rinkin et al. Hip bone mineral density is c EDSS in patients with multiple sclerosis. J Neurol 2006;257:410-418.
    35. Terzi T, Terzi M, Tander B et al. Changes in bone mineral density and bone tabolism markers in premenopausal women with multiple sclerosis and the relati­ onship to clinical variables. J Clin Neurosci 2010;17:1260-1264. Go to original source...
    36. Formica CA, Cosman F, Nieves J et al. Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocortic use. Calcif Tissue Int 1997;61:129-133. Go to original source...
    37. Lambert CP, Lee AR, Evans WJ. Body composition in ambulatory women with multiple sclerosis. Arch Phys Med Rehabil 2002;83:1559-1561. Go to original source...
    38. Mojtahedi MC, Snook EM, Motl RW et al. Bone health in ambulatory individuals with multiple sclerosis: impact of physical activity, glucocorticoid use, and b composition. J Rehabil Res Dev 2008;45:851-861. Go to original source...
    39. Sioka C, Fotopoulos A, Georgiou A et al. Body composition in ambulatory pa­ tients with multiple sclerosis. J Clin Densitom 2011;14:465-470. Go to original source...
    40. Hiremath GS, Cettomai D, Baynes M et al. Vitamin D status and effect of low-do­ se cholecalciferol and high-dose ergocalciferol supplementation in multiple s rosis. Mult Scler 2009;15:735-740. Go to original source...
    41. Barnes MS, Bonham MP, Robson PJ et al. Assessment of 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D3 concentrations in male and female multiple scle­ rosis patients and control volunteers. Mult Scler 2007;13:670-672. Go to original source...
    42. Soilu-Hanninen M, Airas L, Mononen I et al. 25-Hydroxyvitamin D rum at the onset of multiple sclerosis. Mult Scler 2005;11:266-271. Go to original source...
    43. Kragt J, van AB, Killestein J, Dijkstra C et al. Higher levels of 25-hydroxyvit D are associated with a lower incidence of multiple sclerosis only in women. Mult Scler 2009;15:9-15. Go to original source...
    44. Correale J, Ysrraelit MC, Gaitan MI. Immunomodulatory effects of vitamin D in multiple sclerosis. Brain 2009;132:1146-1160. Go to original source...
    45. Confavreux C, Vukusic S, Moreau T et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-1438. Go to original source...
    46. Institute ofMedicine of the National Academies. Dietary reference intakes for c cium and vitamin D. In: Ross CA, Taylor AL, Yaktine AL, Del Valle HB (eds) National Academies Press, Washington, DC, 2010; 1132.
    47. Cattaneo D, DeNuzzo C, Fascia T et al. Risks of falls in subjects with multiple sclerosis. Arch Phys Med Rehabil 2002;83:864-867. Go to original source...
    48. Kirby RL, Ackroyd-Stolarz SA, Brown MG et al. Wheelchair-related accidents caused by tips and falls among noninstitutionalised users of manually propelled wheelchairs in Nova Scotia. Am J Phys Med Rehabil 2004;73:319-330. Go to original source...
    49. Williams P, Frank A, Crawford CM et al. Unrecongised femoral fractures in pa­ tients with paraplegia due to multiple sclerosis. Br Med J 1984;189:501. Go to original source...
    50. Blake AJ, Morgan K, Bendall MJ et al. Falls by eld ce and associated factors. Age Ageing 1988;17:365-372. Go to original source...
    51. Dovio A, Perazzolo L, Osella G et al. Immediate fall of bone formation and tran­ sient increase of bone resorption in the course of high-dose, short-term glucocor­ ticoid therapy in 2004;89:4923-4928. Go to original source...
    52. Bergh FT, Kumpfel T, Schumann E et al. Monthly intravenous methylprednisolo­ ne in relapsing-remitting multiple sclerosis - reduction of enhancing le lesion volume and plasma prolactin concentrations. BMC Neurol 2006;6:19. Go to original source...
    53. Stepan JJ, Havrdova E, Tyblova M et al. Markers of bone remodeling predict rate of bone loss in multiple sclerosis pa Clin Chim Acta 2004; 348 (5):147-154. Go to original source...
    54. Van Staa TP, Laan RF, Barton IP et al. Bone density threshold and other predic­ tors of vertebral fracture in patients receiving oral glucocorticoid therapy. Art Rheum 2003;48:3224-3229. Go to original source...
    55. Van Staa TP, Leufkens HG, Abenhaim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology (Oxford) 2000;39: 1383-1389. Go to original source...
    56. Altinta§ A, Saruhan-Direskeneli G, Benbir G et al. The role of osteopontin: a s red pathway in the pathogenesis of multiple sclerosis and osteoporosis? J Neurol Sci 2009;276:41-44. Go to original source...
    57. Verdel BM, Souverein PC, Egberts TC et al. Use of antidepressant drugs and risk of osteoporotic and non-osteoporotic fractures. Bone 2010;47:604-609. Go to original source...
    58. Diem SJ, Blackwell TL, Stone KL et al. Use of antidepressants and rates of hip bone loss in older women: the study of osteoporotic fractures. Arch Intern Med 2007;167:1240-1245. Go to original source...
    59. Haney EM, Chan BK, Diem SJ et al. for the Osteoporotic Fractures in Men Study Group. Association of low bone mineral density with selective serotonin reuptake inhibitor use by older men. Arch Intern Med 2007;167:1246-1251. Go to original source...
    60. Warden SJ, Robling AG, Haney EM et al. The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of lowdensity lipoprotein receptor-related protein 5 (LRP5). Bone 2010;46:4-12. Go to original source...
    61. Steinman L. A molecula Rev Immunol 2009;9:440^47.
    62. Yuan FL, Li X, Lu WG et al. Regulatory T cells as a bone loss. Biochem Biophys Res Commun 2010;402:173-176. Go to original source...
    63. Ehrhardt GR, Hijikata A, Kitamura H et al. Discriminating gene les of memory B cell subpopulations. J Exp Med 2008;205:1807-1817. Go to original source...
    64. Kurban S, Akpinar Z, Mehmetoglu I. Receptor activator of nuclear factor ligand (RANKL) and osteoprotegerin levels in multiple sclerosis. Mult Scler 2008;I4:43I432.
    65. Qin C, Baba O, Butler WT. Post-translational modifications of sibling proteins and their r 15:126-136.
    66. Bornsen L, Khademi M, Olsson T et al. Osteopontin concentrations are incr in cerebrospinal fluid during attacks of multiple sclerosis. Mult Scler 2011; 17:32-42. Go to original source...
    67. Comabella M, Pericot I, Goertsches R et sclerosis. J Neuroimmunol 2005;158:231-239. Go to original source...
    68. Confavreux C, Vukusic S, Moreau T, Adeleine P. Relapses and ability in multiple sclerosis. N Engl J Med 2000;343:1430-1438. Go to original source...
    69. Leray E, Yaouanq J, Le PE et al. Evidence fo in multiple sclerosis. Brain 2010;133:1900-1913. Go to original source...
    70. Nilsagard Y, Lundholm C, Denison E et al. Predicting accidental falls in with multiple sclerosis - a longitudinal study. Clin Rehabil 2009;23:259-269. Go to original source...
    71. Cattaneo D, DeNuzzo C, Fascia T et al. Risks of falls in subjects with multi sclerosis. Arch Phys Med Rehabil 2002;83:864-867. Go to original source...
    72. Hearn AP, Silber E. Osteoporosis in multiple sclerosis. Mult Scler 2010; 16: 1031-1043. Go to original source...
    73. Weinstein RS. Clinical practice. Glucocorticoid-induced bone disease. N Engl J Med 2011;365:62-70. Go to original source...
    74. Kanis JA, McCloskey E, Johansson H et al. FRAX(reg) with and without Bone Mineral Density. Calcif Tissue Int 2011;90:1-13. Go to original source...
    75. Cakt BD, Nacir B, Genc H et al. Cycling progressive resistance training for ple with multiple sclerosis: a randomized controlled study. Am J Phys Med Rehabil 2010; 89:446^57. Go to original source...
    76. Dalgas U, Stenager E, Jakobsen J et al. Resistance training improves muscle strength and functional capacity in multiple sclerosis. Neurology 2009;73:1478-1484. Go to original source...
    77. Stroud NM, Minahan CL. The impact of regular physical activity on fatigue, de­ pression and qualit Outcomes 2009;7:68. Go to original source...
    78. Snook EM, Motl RW. Effect of exercise training on walking mobility sclerosis: a meta-analysis. Neurorehabil Neural Repair 2009;23:108-116. Go to original source...
    79. Rubenstein LZ. Falls in older people: epidemiology, risk factors and strategies prevention 1. Age Ageing 2006; 35(Suppl 2):ii37-ii41. Go to original source...
    80. Ryan AS, Ivey FM, Hurlbut DE et al. Regional bone mineral density after resisti­ ve training in young and older men and women. Scand J Med Sci Sports 2004;14: 16-23. Go to original source...
    81. Bubbear JS, Gall A, Middleton FR et al. Early treatment with zoledronic acid pre­ vents bone 22:271-279.
    82. Zehnder Y, Risi S, Michel D et al. Prevention of bone los 2 years with alendronate. J Bone Miner Res 2004;19:1067-1074. Go to original source...
    83. Yang Li C, Majeska RJ, Laudier DM et al. High-dose risedronate treatment pa ally preserves cancellous bone mass and microarchitecture during long-term dis­ use. Bone 2005;37:287-295. Go to original source...
    84. Saag KG, Zanchetta JR, Devogelaer JP et al. Effects of teriparatide versus alen­ dronate for treating glucocorticoid-induced osteoporosis: thirty-six-mont of a randomized, double-blind, controlled trial. Arthritis Rheum 2009;60: 3346-3355. Go to original source...
    85. Turner RT, Evans GL, Lotinun S et al. Dose-response effects of intermitte on cancellous bone in hindlimb unloaded rats. J Bone Miner Res 2007;22:64-71. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.